Double-blind, Randomized, Vehicle- and Comparator-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of LAS41007 in the Treatment of Actinic Keratosis
Phase 3
Completed
- Conditions
- Actinic Keratosis
- Interventions
- Drug: LAS41007Drug: LASW1510Drug: vehicle of LAS41007
- First Posted Date
- 2010-12-23
- Last Posted Date
- 2012-07-24
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 889
- Registration Number
- NCT01265602
- Locations
- 🇩🇪
Almirall Investigational Site, Vechta, Germany
Study to Investigate Skin Conditions and Patient Assessment of LAS 41002 in the Treatment of Atopic Eczema
Phase 2
Completed
- Conditions
- Atopic Eczema
- Interventions
- Drug: LAS 41002Drug: Active
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2010-07-12
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 20
- Registration Number
- NCT01119313
- Locations
- 🇩🇪
Almirall Investigational Sites#1, Hamburg, Germany
Study to Investigate Dose-related Efficacy of LAS41004 in the Treatment of Psoriasis
Phase 2
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: LAS 41004Drug: PlaceboDrug: LAS 41004 dosage 6Drug: Reference
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 20
- Registration Number
- NCT01119339
- Locations
- 🇩🇪
Almirall Investigational Sites#1, Mahlow, Germany
Efficacy and Safety of LAS41003 in the Treatment of Intertriginous Candida Infections
Phase 2
Completed
- Conditions
- Candidiasis
- Interventions
- Drug: LAS189962Drug: LAS189961Drug: LAS41003
- First Posted Date
- 2010-04-13
- Last Posted Date
- 2012-07-04
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 137
- Registration Number
- NCT01102387
- Locations
- 🇩🇪
Investigational Site #5, Augsburg, Germany
🇩🇪Investigational Site #2, Berlin, Germany
🇩🇪Investigational Site #4, Bad Saarow, Germany
Efficacy and Safety of LAS41003 in the Treatment of Inflammatory Tinea Pedis
Phase 2
Completed
- Conditions
- Tinea Pedis
- Interventions
- Drug: LAS41003Drug: LAS189962Drug: LAS189961
- First Posted Date
- 2010-03-31
- Last Posted Date
- 2012-07-09
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 120
- Registration Number
- NCT01096472
- Locations
- 🇩🇪
Investigational Site #2, Berlin, Germany
🇩🇪Investigational Site #1, Hamburg, Germany
Efficacy and Safety of LAS41003 in the Treatment of Superficial Infected Eczema
Phase 2
Completed
- Conditions
- Eczema
- Interventions
- Drug: LAS41003Drug: LAS189962Drug: LAS189961
- First Posted Date
- 2009-11-26
- Last Posted Date
- 2010-07-09
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 150
- Registration Number
- NCT01020994
- Locations
- 🇩🇪
Investigational Site, Bochum, Germany
Efficacy and Safety Study of LAS41007 in the Treatment of Actinic Keratosis
Phase 2
Completed
- Conditions
- Actinic Keratosis
- Interventions
- Drug: LAS41007 o.d.Drug: LAS106521Drug: LAS41007 b.i.d.
- First Posted Date
- 2009-10-08
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 100
- Registration Number
- NCT00991861
- Locations
- 🇩🇪
Investigational Site, Hamburg, Germany
Study on the Efficacy of LAS41005 in the Treatment of Actinic Keratosis
Phase 3
Completed
- Conditions
- Actinic Keratosis
- Interventions
- Drug: LAS106521Drug: Placebo GelDrug: LAS41005
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2015-07-28
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 470
- Registration Number
- NCT00987246
- Locations
- 🇩🇪
Almirall Facility Site#01, Berlin, Germany
🇩🇪Almirall Facility Site#04, Buxtehude, Germany
🇩🇪Almirall Facility Site#30, Dresden, Germany
Standardized sTudy With Almotriptan in eaRly Treatment of Migraine
Completed
- Conditions
- Migraine
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2015-06-01
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 501
- Registration Number
- NCT00725140
- Locations
- 🇮🇹
26 GPs across Italy, Diverse, Italy
🇪🇸26 GP practices across Spain, Diverse, Spain
🇫🇷28 GPs across France, Diverse, France
© Copyright 2025. All Rights Reserved by MedPath